The Tenacious CDMO: Formulated Solutions' Custom Approach to Complex Pharmaceutical Development

The Silicon Review

In the high-stakes world of pharmaceutical development, the distance between a promising formulation and a market-ready product is paved with obstacles. Regulatory hurdles, manufacturing scalability challenges, analytical validation requirements, and packaging complexities each present opportunities for delay, cost overrun, or outright failure. For emerging pharmaceutical companies and established brands alike, finding a contract development and manufacturing organization that combines technical expertise with genuine partnership orientation has become increasingly critical.

Formulated Solutions was founded in 1999 to fill this exact gap. Headquartered in Largo, Florida, with a second major facility in Cleveland, Tennessee, the company has spent over two decades building a reputation for tackling complex formulation challenges that others avoid. Under the leadership of Founder and Board Member Eric Dann, the organization has grown into a tenacious, customer-centric CDMO specializing in semi-solid, liquid, and aerosol systems for Rx therapeutics, consumer health products, and medical devices. With over 650 products developed and enhanced, regulatory approvals from more than 17 global bodies including the FDA, Health Canada, ANVISA, and the EMA, and partnerships with most of the top 12 pharmaceutical companies, Formulated Solutions has established itself as a trusted partner for products that demand extraordinary attention to detail.

The company's revenue model is built on project-based development fees and long-term manufacturing contracts. Clients engage Formulated Solutions for formulation and process development, analytical development, regulatory affairs support, and commercial manufacturing across small-scale clinical batches through large-scale production. The company's integrated service model generates revenue at multiple points in the product lifecycle, with successful development projects naturally transitioning into manufacturing contracts that provide recurring income over years or decades. Strategic investments in proprietary technologies, including whipped delivery systems, cryogenic delivery platforms, and high-solid powder spray technologies, create additional value by enabling differentiated products that command premium pricing.

The Founder's Vision as a Quality Foundation

Eric Dann founded Formulated Solutions with a philosophy that continues to define the company's approach: quality is not a checkpoint but a cultural foundation. Over 20 percent of the organization's employees are dedicated to quality functions, an extraordinary ratio that reflects Dann's commitment to building quality into every process rather than inspecting it at the end. This investment in quality infrastructure has produced an impeccable regulatory track record, with successful audits from over 17 regulatory bodies worldwide. For clients whose products directly impact patient health, this reliability is non-negotiable. It generates trust that sustains long-term partnerships and attracts new clients who recognize that quality failures in pharmaceutical manufacturing can be catastrophic. The quality culture also creates operational efficiencies that protect margins while delivering superior outcomes.

The Proprietary Technology Portfolio for Competitive Differentiation

Formulated Solutions has deliberately invested in developing proprietary technologies that enable clients to create differentiated products. The whipped delivery system, cryogenic delivery platform, and high-solid powder spray technologies represent solutions to complex formulation challenges that generic CDMOs cannot address. These technologies allow clients to develop products with enhanced stability, improved bioavailability, or novel delivery mechanisms that command competitive advantage in the marketplace. For Formulated Solutions, the proprietary portfolio generates revenue through technology licensing, premium pricing for specialized services, and client lock-in; once a product is developed around a proprietary platform, manufacturing must remain with the technology owner. The portfolio also attracts innovation-focused clients seeking partners who can help them push beyond conventional formulation boundaries.

The Dual-Facility Manufacturing Network for Scalability

Formulated Solutions operates two major facilities that provide clients with manufacturing flexibility and capacity assurance. The 220,000-square-foot Largo headquarters integrates laboratories, offices, and cGMP production space, supported by 260,000 square feet of offsite warehouse storage. The 455,000-square-foot Cleveland facility, FDA-approved with a rich pharmaceutical history, adds significant high-speed production capacity for aerosols, tubes, nasal sprays, and oral dose liquids. This dual-facility network enables the company to scale from clinical batches to commercial production without requiring clients to requalify new manufacturing sites. It also provides business continuity assurance; if one facility faces disruption, the other can maintain supply. For clients whose products treat chronic conditions, this reliability is essential, justifying long-term manufacturing contracts that generate stable recurring revenue.

The End-to-End Integrated Service Model

Formulated Solutions offers a truly integrated service suite spanning the entire product lifecycle, from initial concept through commercial launch and post-market surveillance. Innovation teams collaborate with clients to solve complex formulation challenges. Formulation and process development experts craft reproducible manufacturing methods. Analytical development scientists validate methods and characterize products. Regulatory affairs specialists navigate submission requirements across global markets. Manufacturing teams produce clinical and commercial batches. Packaging engineers design container closure systems that protect product integrity. This integration eliminates the handoff risks that plague fragmented development programs, where issues identified late in development force expensive reformulation. For Formulated Solutions, the integrated model generates revenue at every stage while reducing client risk, creating powerful incentives for clients to consolidate their development and manufacturing with a single trusted partner.

For pharmaceutical companies seeking a CDMO partner capable of handling complexity with reliability and innovation, Formulated Solutions offers a compelling combination of technical depth, quality culture, and long-term orientation. Eric Dann's founding vision of quality as cultural foundation has produced an organization where over 20 percent of employees focus on quality, where regulatory track records remain impeccable, and where proprietary technologies enable differentiated products. With over 650 products developed, partnerships with the world's leading pharmaceutical companies, and facilities designed for scalability and compliance, Formulated Solutions stands ready to help clients transform extraordinary ideas into market-ready realities.

Eric Dann, Founder and Board Member